Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 7936-7941

  Pui, Ching Hon ^a   Pei, Deqing ^b   Sandlund, John T ^b   Campana, Dario ^b   Ribeiro, Raul C ^b   Razzouk, Bassem I ^b   Rubnitz, Jeffrey E ^b   Howard, Scott C ^b   Hijiya, Nobuko ^b   Jeha, Sima ^b   Cheng, Cheng ^b   Downing, James R ^b   Evans, William E ^b   Relling, Mary V ^b   Hudson, Melissa ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; TENIPOSIDE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CHILD; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EWING SARCOMA; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MYELODYSPLASIA; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SECOND CANCER; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME; INFANT; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; REMISSION; RISK FACTOR; SKULL IRRADIATION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; ETOPOSIDE; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TENIPOSIDE;

EID: 32944481786     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.0033     Document Type: Article

References (40)

1. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90-German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310-3322, 2000
2. Gaynon PS, Trigg ME, Heerema NA, et al: Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14:2223-2233, 2000
3. Harms DO, Janka-Schaub GE: Cooperative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89 and 92. Leukemia 14:2234-2239, 2000
4. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218, 2001
5. Gustafsson G, Schmiegelow K, Forestier E, et al: Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation-Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 14:2267-2275, 2000
6. Pui C-H, Sandlund JT, Pei D, et al: Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 290:2001-2007, 2003
7. Pui C-H, Dodge RK, Look AT, et al: Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy Studies VIII, IX, and X. J Clin Oncol 9:1341-1347, 1991
8. Pui C-H, Boyett JM, Rivera GK, et al: Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St. Jude Children's Research Hospital. Leukemia 14:2286-2294, 2000
9. Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998
10. Pui C-H, Mahmoud HH, Rivera GK, et al: Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 92:411-415, 1998
11. Pui C-H, Sandlund JT, Pei D, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood 104:2690-2696, 2004
12. Kishi S, Griener J, Cheng C, et al: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21:3084-3091, 2003
13. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
14. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data. New York, NY, Wiley, 2002
15. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
16. Pui C-H: Recent advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 103:85-95, 2004
17. Johansen OJ, Moe PJ: Relapse rate after cessation of therapy in childhood leukemia: A follow-up report on 277 cases from the five Nordic countries. Acta Paediatr Scan 69:663-666, 1980
18. Miller DR, Coccia PF, Bleyer WA, et al: Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Children's Cancer Study Group. J Clin Oncol 7:1807-1815, 1989
19. Rautonen J, Siimes MA: Can late relapse be predicted at initial diagnosis in childhood acute lymphoblastic leukemia? Eur J Haematol 43:215-219, 1989
20. Nygaard R, Moe PJ, Brincker H, et al: Late relapses after treatment for acute lymphoblastic leukemia in childhood: A population-based study from the Nordic countries. Med Pediatr Oncol 17:45-47, 1989
21. Kawashima K, Nagura E-I, Yamada K, et al: Leukemia relapse in long-term survivors of acute leukemia. Cancer 56:88-94, 1985
22. Miller DR, Leikin SL, Albo VC, et al: Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Study Group. J Clin Oncol 7:316-325, 1989
23. Jankovic M, Fraschini D, Amici A, et al: Outcome after cessation of therapy in childhood acute lymphoblastic leukaemia: The Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP). Eur J Cancer 29A: 1839-1843, 1993
24. Miniero R, Saracco P, Pastore G, et al: Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: A 10-year follow-up study-Italian Association of Pediatric Hematology-Oncology (AIEOP). Med Pediatr Oncol 24:71-76, 1995
25. Pui C-H, Cheng C, Leung W, et al: Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349:640-649, 2003
26. Rizzari C, Valsecchi MG, Aricò M, et al: Outcome of very late relapse in children with acute lymphoblastic leukemia. Haematologica 89:427-434, 2004
27. Vora A, Frost L, Goodeve A, et al: Late relapsing childhood lymphoblastic leukemia. Blood 92:2334-2337, 1998
28. Pui C-H, Belling MV: Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 109:13-23, 2000
29. Belling MV, Rubnitz JE, Rivera GK, et al: High incidence of secondary brain tumors after radiotherapy and antimetabolites. Lancet 354: 34-39, 1999
30. Pui C-H, Boyett JM, Belling MV, et al: Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 17:818-824, 1999
31. Shuster JJ, Wacker P, Pullen J, et al: Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 16: 2854-2863, 1998
32. Chessells JM, Richards SM, Bailey CC, et al: Gender and treatment outcome in childhood lymphoblastic leukaemia: Report from the MRC UKALL trials. Br J Haematol 89:364-372, 1995
33. Harbott J, Viehmann S, Borkhardt A: Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 90:4933-4937, 1997
34. Seeger K, Adams HP, Buchwald D, et al: TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Munster Study Group. Blood 91:1716-1722, 1998
35. Seeger K, Buchwald D, Taube T, et al: TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood: Berlin-Frankfurt- Munster Study Group. Leukemia 13:1469-1470, 1999
36. Pui C-H, Campana C, Evans WE: Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol 2:597-607, 2001
37. Szczepanski T, Orfão A, van der Velden VHJ, et al: Minimal residual disease in leukaemia patients. Lancet Oncol 2:409-417, 2001
38. Campana D: Determination of minimal residual disease in leukemia patients. Br J Haematol 121:823-838, 2003
39. Pui C-H, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 350:1535-1548, 2004
40. Pui C-H: Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol 21:179-181, 2003